Trubion Pharmaceuticals Announces Presentation Of Positive Data From Phase IIb And Re-treatment Studies With TRU-015 In Patients With Arthritis
Nov 9th 2007Drug InformationArthritis
Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced presentation of positive data from a Phase IIb study that showed that Trubion’s TRU-015 for rheumatoid arthritis (RA) provided statistically significant efficacy after a single infusion of 800 mg or 1,600 mg. In addition, Trubion also announced presentation of data showing that repeat administration with TRU-015 was well tolerated and resulted in a consistent pharmacokinetic (PK) and pharmacodynamic (PD) profile. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
